BioSpace News Archive

The company also terminated a Phase III trial of its TGFB inhibitor as a treatment for metastatic pancreatic ductal adenocarcinoma, though that drug will continue to be tested as a treatment for colorectal cancer.

Less than two years after launch, the startup posts positive Phase II results and heads into Phase III trials for major depressive disorder with a new CEO.

The Netherlands-based immunology company said Wednesday it brought in $1.1 billion by selling more than two million shares in the U.S. and Europe.

Next-gen biomanufacturers are particularly susceptible to the challenges inherent in manufacturing cell and gene therapies, risking getting derailed by unexpected costs for already-tight budgets.

Tuesday’s partnership will dig into Flagship’s deep ecosystem of companies and technologies to discover medicines in line with Pfizer’s core strategic areas.

Following the full approval of Leqembi, the CMS suggests expanding its coverage of beta-amyloid PET scans, which could improve the uptake of novel Alzheimer’s disease treatments.

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), announced today that it has reached an agreement yesterday with PharmaTher Inc.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, announced the five founding members of the Alliance for Genomic Discovery.

Co-Diagnostics, Inc. today announced grants awarded by the Bill & Melinda Gates Foundation related to the tuberculosis (TB) and human papillomavirus (HPV) tests on the Company’s Co-Dx PCR Home™ platform.

Applied DNA Sciences, Inc. today announced the participation of LineaRx, Inc., its majority-owned biotherapeutics subsidiary, in upcoming mRNA industry conferences in Boston.